
|Videos|April 28, 2017
How Cabozantinib is Being Used in Practice for Patients With RCC
Author(s)Daniel James George, MD
Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
2
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
3
FDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC
4
NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer
5



































